Join us for a dynamic 90-minute webinar exploring the latest advancements in early-phase clinical trials targeting Hepatitis B (HBV) and Hepatitis D (HDV). As novel antiviral therapies and gene-editing technologies offer hope for functional cures, early-phase trials face unique challenges in balancing rapid development with safety and precision.
This session will delve into strategies that enhance trial flexibility, patient recruitment, and cohort management to navigate the complex landscapes of HBV and HDV treatment.
Industry leaders and researchers will discuss cutting-edge trial designs, emerging biomarkers, and adaptive strategies that are redefining early-phase success in infectious disease research.
Don’t miss this opportunity to gain insights into the future of HBV and HDV clinical development.
Overcoming challenges associated with the current situation in Ukraine while conducting HBV/HDV clinical trials
Round Table Discussion